TREMFYA® benefits patients
with severe Pso.

  • Male, aged 53, presented with severe chronic plaque psoriasis in January 2019.
  • Multidrug resistant and unresponsive to traditional systemic drugs.
  • With TREMFYA®, baseline PASI 42 decreased to PASI 3 at 16 weeks and PASI 0 at 36 weeks.

 

Baseline


  

Week 16


  

Week 36
 
 
TREMFYA® helped 63.2% of patients achieve PASI 100 and 78.9% achieve PASI 90 at 12 months.3
 
 
 
 
 
 
REFERENCES SEE MORE OF THE LATEST DATA
ON THE JANSSEN MEDICAL CLOUD™		 PRESCRIBING
INFORMATION

 
TREMFYA® is indicated for adults with moderate-to-severe plaque
psoriasis (Pso) who are candidates for systemic therapy.10

Tremfya®, alone or in combination with methotrexate (MTX), is indicated
for the treatment of active psoriatic arthritis in adult patients who have
had an inadequate response or who have been intolerant to a prior
disease-modifying antirheumatic drug (DMARD) therapy. 10

Please ensure you review your local Prescribing Information and/or
Summary of Product Characteristics and directly consult
your local Janssen affiliate to address questions.		 Privacy notice  Legal notice

This is published by Janssen Pharmaceutica NV which is solely responsible
for its content. It is intended for EMEA Healthcare professionals.
Third party trademarks used herein are trademarks of their respective owners.
Date of preparation: March 2021.  CP-214600